ZAI LAB LTD-ADR (ZLAB) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ZLAB • US98887Q1040

18 USD
+1.02 (+6.01%)
At close: Feb 6, 2026
18.05 USD
+0.05 (+0.28%)
After Hours: 2/6/2026, 8:12:37 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, ZLAB scores 3 out of 10 in our fundamental rating. ZLAB was compared to 523 industry peers in the Biotechnology industry. ZLAB has a bad profitability rating. Also its financial health evaluation is rather negative. ZLAB is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ZLAB had negative earnings in the past year.
  • ZLAB had a negative operating cash flow in the past year.
  • ZLAB had negative earnings in each of the past 5 years.
  • In the past 5 years ZLAB always reported negative operating cash flow.
ZLAB Yearly Net Income VS EBIT VS OCF VS FCFZLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -17.84%, ZLAB is in the better half of the industry, outperforming 77.71% of the companies in the same industry.
  • With a decent Return On Equity value of -27.21%, ZLAB is doing good in the industry, outperforming 78.86% of the companies in the same industry.
Industry RankSector Rank
ROA -17.84%
ROE -27.21%
ROIC N/A
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ZLAB Yearly ROA, ROE, ROICZLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • ZLAB has a Gross Margin of 61.52%. This is in the better half of the industry: ZLAB outperforms 78.67% of its industry peers.
  • In the last couple of years the Gross Margin of ZLAB has declined.
  • The Profit Margin and Operating Margin are not available for ZLAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
ZLAB Yearly Profit, Operating, Gross MarginsZLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ZLAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ZLAB has more shares outstanding than it did 1 year ago.
  • ZLAB has more shares outstanding than it did 5 years ago.
  • ZLAB has a worse debt/assets ratio than last year.
ZLAB Yearly Shares OutstandingZLAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ZLAB Yearly Total Debt VS Total AssetsZLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • Based on the Altman-Z score of 0.32, we must say that ZLAB is in the distress zone and has some risk of bankruptcy.
  • ZLAB has a better Altman-Z score (0.32) than 61.90% of its industry peers.
  • ZLAB has a Debt/Equity ratio of 0.27. This is a healthy value indicating a solid balance between debt and equity.
  • ZLAB has a Debt to Equity ratio of 0.27. This is in the lower half of the industry: ZLAB underperforms 67.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Altman-Z 0.32
ROIC/WACCN/A
WACC11.05%
ZLAB Yearly LT Debt VS Equity VS FCFZLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

  • ZLAB has a Current Ratio of 2.87. This indicates that ZLAB is financially healthy and has no problem in meeting its short term obligations.
  • ZLAB has a Current ratio of 2.87. This is in the lower half of the industry: ZLAB underperforms 65.33% of its industry peers.
  • ZLAB has a Quick Ratio of 2.68. This indicates that ZLAB is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ZLAB (2.68) is worse than 66.29% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.68
ZLAB Yearly Current Assets VS Current LiabilitesZLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.63% over the past year.
  • The Revenue has grown by 24.14% in the past year. This is a very strong growth!
  • Measured over the past years, ZLAB shows a very strong growth in Revenue. The Revenue has been growing by 98.34% on average per year.
EPS 1Y (TTM)29.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)24.14%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%13.27%

3.2 Future

  • ZLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 81.52% yearly.
  • Based on estimates for the next years, ZLAB will show a very strong growth in Revenue. The Revenue will grow by 33.32% on average per year.
EPS Next Y25.5%
EPS Next 2Y21.14%
EPS Next 3Y18.34%
EPS Next 5Y81.52%
Revenue Next Year27.23%
Revenue Next 2Y28.92%
Revenue Next 3Y32.97%
Revenue Next 5Y33.32%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ZLAB Yearly Revenue VS EstimatesZLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
ZLAB Yearly EPS VS EstimatesZLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 50 100 150

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZLAB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ZLAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZLAB Price Earnings VS Forward Price EarningsZLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZLAB Per share dataZLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • ZLAB's earnings are expected to grow with 18.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.14%
EPS Next 3Y18.34%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ZLAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZAI LAB LTD-ADR

NASDAQ:ZLAB (2/6/2026, 8:12:37 PM)

After market: 18.05 +0.05 (+0.28%)

18

+1.02 (+6.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-03
Inst Owners33.5%
Inst Owner Change3.33%
Ins Owners1.73%
Ins Owner Change17.98%
Market Cap1.99B
Revenue(TTM)441.63M
Net Income(TTM)-206.81M
Analysts78.57
Price Target18.77 (4.28%)
Short Float %3.78%
Short Ratio4.47
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.17%
Min EPS beat(2)1.96%
Max EPS beat(2)32.39%
EPS beat(4)3
Avg EPS beat(4)10.97%
Min EPS beat(4)-12.04%
Max EPS beat(4)32.39%
EPS beat(8)6
Avg EPS beat(8)14.73%
EPS beat(12)9
Avg EPS beat(12)28.23%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.72%
Min Revenue beat(2)-17.27%
Max Revenue beat(2)-14.17%
Revenue beat(4)0
Avg Revenue beat(4)-10.92%
Min Revenue beat(4)-17.27%
Max Revenue beat(4)-1.65%
Revenue beat(8)2
Avg Revenue beat(8)-5.45%
Revenue beat(12)4
Avg Revenue beat(12)-3.59%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.86%
PT rev (3m)-33.12%
EPS NQ rev (1m)0.17%
EPS NQ rev (3m)-121.64%
EPS NY rev (1m)-8.78%
EPS NY rev (3m)-32.22%
Revenue NQ rev (1m)-0.08%
Revenue NQ rev (3m)-34.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-11.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.52
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB 2.84
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.32
Fwd EYN/A
FCF(TTM)-1.9
FCFYN/A
OCF(TTM)-1.63
OCFYN/A
SpS3.99
BVpS6.86
TBVpS6.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.84%
ROE -27.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.52%
FCFM N/A
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
F-Score4
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 211.53%
Cap/Sales 6.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.68
Altman-Z 0.32
F-Score4
WACC11.05%
ROIC/WACCN/A
Cap/Depr(3y)305.55%
Cap/Depr(5y)287.72%
Cap/Sales(3y)10.07%
Cap/Sales(5y)13.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y25.5%
EPS Next 2Y21.14%
EPS Next 3Y18.34%
EPS Next 5Y81.52%
Revenue 1Y (TTM)24.14%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%13.27%
Revenue Next Year27.23%
Revenue Next 2Y28.92%
Revenue Next 3Y32.97%
Revenue Next 5Y33.32%
EBIT growth 1Y32.74%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.9%
EBIT Next 3Y28.89%
EBIT Next 5Y32.27%
FCF growth 1Y30.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.29%
OCF growth 3YN/A
OCF growth 5YN/A

ZAI LAB LTD-ADR / ZLAB FAQ

Can you provide the ChartMill fundamental rating for ZAI LAB LTD-ADR?

ChartMill assigns a fundamental rating of 3 / 10 to ZLAB.


What is the valuation status for ZLAB stock?

ChartMill assigns a valuation rating of 0 / 10 to ZAI LAB LTD-ADR (ZLAB). This can be considered as Overvalued.


What is the profitability of ZLAB stock?

ZAI LAB LTD-ADR (ZLAB) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for ZLAB stock?

The Earnings per Share (EPS) of ZAI LAB LTD-ADR (ZLAB) is expected to grow by 25.5% in the next year.